{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:55:42Z","timestamp":1790276142863,"version":"4.1.0"},"reference-count":34,"publisher":"Impact Journals, LLC","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,16]]},"DOI":"10.18632\/oncotarget.10588","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T04:10:06Z","timestamp":1468469406000},"page":"53037-53046","source":"Crossref","is-referenced-by-count":33,"title":["An appraisal of drug development timelines in the Era of precision oncology"],"prefix":"10.18632","volume":"7","author":[{"given":"Denis Leonardo","family":"Jardim","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schwaederle","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Cancer Genome Atlas Research N","year":"2012","journal-title":"Nature"},{"key":"2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"key":"3","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Pao","year":"2013","journal-title":"Clin Cancer Res"},{"key":"4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.28661","article-title":"RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"120","author":"Norton","year":"2014","journal-title":"Cancer"},{"key":"5","unstructured":"Food and Drug Administration and US Department of Health and Human Services. Mar 2006. Critical Path Report. http:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/CriticalPathInitiative\/CriticalPathOpportunitiesReports\/UCM077254.pdf."},{"key":"6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrclinonc.2011.190","article-title":"Role of randomized phase III trials in an era of effective targeted therapies","volume":"9","author":"Schilsky","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"7","first-page":"107","article-title":"Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval","author":"Kurzrock","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrclinonc.2012.22","article-title":"Drug development and clinical trials\u2014the path to an approved cancer drug","volume":"9","author":"Gilliland","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrclinonc.2012.14","article-title":"Hurdles in anticancer drug development from a regulatory perspective","volume":"9","author":"Bergh","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccr.2010.11.033","article-title":"ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time","volume":"18","author":"Minna","year":"2010","journal-title":"Cancer Cell"},{"key":"11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: first global approval","volume":"74","author":"Clark","year":"2014","journal-title":"Drugs"},{"key":"12","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1200\/JCO.2008.21.1961","article-title":"Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?","volume":"27","author":"Edwards","year":"2009","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2006.09.0803","article-title":"Economics of new oncology drug development","volume":"25","author":"Grabowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2009.27.5404","article-title":"Equipoise lost: ethics, costs, and the regulation of cancer clinical research","volume":"28","author":"Kurzrock","year":"2010","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.2008.18.9621","article-title":"Cancer: the road to Amiens","volume":"27","author":"Kurzrock","year":"2009","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/1535-7163.MCT-06-0674","article-title":"Uncommon tumors and exceptional therapies: paradox or paradigm?","volume":"6","author":"Kurzrock","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrclinonc.2012.127","article-title":"Overcoming implementation challenges of personalized cancer therapy","volume":"9","author":"Mills","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrclinonc.2014.202","article-title":"Pragmatic issues in biomarker evaluation for targeted therapies in cancer","volume":"12","author":"Hamilton","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"19","first-page":"11047","article-title":"Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval","volume":"32","author":"Kurzrock","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"20","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1158\/1078-0432.CCR-12-0178","article-title":"Outcomes of phase II clinical trials with single-agent therapies in advanced\/metastatic non-small cell lung cancer published between 2000 and 2009","volume":"18","author":"Kurzrock","year":"2012","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1200\/JCO.2009.23.6018","article-title":"Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial","volume":"27","author":"Kurzrock","year":"2009","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMsa1200223","article-title":"Regulatory review of novel therapeutics-comparison of three regulatory agencies","volume":"366","author":"Ross","year":"2012","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1078-0432.CCR-13-1761","article-title":"Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis oncompanion diagnostics","volume":"20","author":"Pfaff","year":"2014","journal-title":"Clin Cancer Res"},{"key":"24","first-page":"4422","article-title":"and Herbst RS","volume":"20","author":"Bunn","year":"2014","journal-title":"\u201cCompanion diagnostics\u201d: has their time come and gone? Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-11-2393","article-title":"Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target","volume":"18","author":"Janne","year":"2012","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"27","unstructured":"Food and Drug Administration (FDA). Drugs @FDA. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/."},{"key":"28","unstructured":"Federal Register. Search Documents https:\/\/www.federalregister.gov\/articles\/search."},{"key":"29","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1056\/NEJMp1402114","article-title":"Drug development and FDA approval, 1938-2013","volume":"370","author":"Darrow","year":"2014","journal-title":"N Engl J Med"},{"key":"30","unstructured":"American Society of Clinical Oncology meeting website. http:\/\/meetinglibrary.asco.org\/abstracts."},{"key":"31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/1078-0432.CCR-13-2103","article-title":"Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs","volume":"20","author":"Hong","year":"2014","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdf202","article-title":"Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs","volume":"13","author":"Saijo","year":"2002","journal-title":"Ann Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Gwyther","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Winkler","year":"1981","journal-title":"Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:06:37Z","timestamp":1589277997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":34,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,8,16]]}},"alternative-id":["10588","27419632"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10588","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]}}}